Truist raised the firm’s price target on Catalyst Pharmaceuticals to $30 from $25 and keeps a Buy rating on the shares. The company’s Q2 results were “impressive”, with Agamree off to a strong start, driving its management to raise guide by 36% at the mid-point, the analyst tells investors in a research note. Firdapse approval in Japan in the second half of 2024, followed by inroads in China, could fuel the stock’s continued momentum, Truist added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals backs FY24 revenue view $455M-$475M,
- Catalyst Pharmaceuticals reports Q2 EPS 33c, consensus 26c
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
- Catalyst Pharmaceutical Partners (CPRX) Q2 Earnings Cheat Sheet
- Catalyst Pharmaceuticals enters exclusive agreement with Kye Pharmaceuticals